|1.||Zhao, Ying-Yong: 7 articles (10/2014 - 10/2010)|
|2.||Lin, Rui-Chao: 5 articles (01/2013 - 10/2010)|
|3.||Wei, Feng: 3 articles (01/2014 - 10/2012)|
|4.||Bai, Xu: 3 articles (01/2014 - 10/2012)|
|5.||Cheng, Xian-Long: 3 articles (01/2013 - 04/2011)|
|6.||Sun, Wen-Ji: 3 articles (12/2011 - 10/2010)|
|7.||Zhang, Yongmin: 3 articles (12/2011 - 10/2010)|
|8.||Chen, Dan-Qian: 2 articles (10/2014 - 01/2014)|
|9.||Chen, Hua: 2 articles (10/2014 - 01/2014)|
|10.||Hu, Xiaoyun: 2 articles (02/2013 - 01/2013)|
01/30/2013 - "In vivo experiment also confirmed that FA-ergone-BSANPs represent a FR-targeted chemotherapeutic that can produce potent activity against FR-positive tumors. "
10/01/2010 - "The results showed that ergone had more selective cytotoxic activity against cancer cells than against normal cells."
10/01/2010 - "Furthermore, the cytotoxic effects of ergone on normal human cells (HUVEC) were smaller than on cancer cells. "
10/01/2010 - "Ergone displayed remarkable anticancer activity against HepG2, Hep-2, and Hela cancer cells, of which HepG2 cells were the most sensitive. "
02/01/2013 - "The purpose of this study was to evaluate the potent ergone formulations for cancer chemotherapy, the liposomal formulations were less toxic and provide longer systemic circulation time were selected as candidates of nanocarriers for ergone. "
|2.||Chronic Kidney Failure (Chronic Renal Failure)
10/09/2012 - "These biochemical changes in serum metabolites are related to the perturbations of amino acid metabolism and lecithin metabolism, which may be helpful to further understand the chronic renal failure and therapeutic mechanisms of ergone. "
10/09/2012 - "Coupled with blood biochemistry and kidney histopathology results, the significant difference in metabolic profiling between adenine-induced chronic renal failure group and the ergone treated group by using pattern recognition analysis indicated that changes in global serum metabolites occurred. "
10/09/2012 - "We investigated the therapeutic effects and mechanism of ergone on a chronic renal failure model of rats induced by adenine. "
01/25/2013 - "Ultra performance liquid chromatography coupled with quadrupole time-of-flight high-sensitivity mass spectrometry and a novel mass spectrometry(Elevated Energy) (MS(E)) data collection technique was employed to investigate metabonomic characters of chronic renal failure (CRF) induced adenine and the protective effects of ergosta-4,6,8(14),22-tetraen-3-one (ergone). "
10/09/2012 - "Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm."
|3.||Kidney Diseases (Kidney Disease)
|4.||Hepatocellular Carcinoma (Hepatoma)
12/01/2011 - "Early administration of ergone may prevent the progression of renal injury and the subsequent renal fibrosis in AA nephropathy."
01/25/2013 - "Ergosta-4,6,8(14),22-tetraen-3-one (ergone), isolated from the medicinal fungus Polyporus umbellatus, has been proven to prevent the progression of renal injury and the subsequent renal fibrosis. "
10/09/2012 - "Ergosta-4,6,8(14),22-tetraen-3-one (ergone) has been proven to prevent the progression of renal injury and the subsequent renal fibrosis. "
|1.||Drug Therapy (Chemotherapy)